High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders

Current Pharmaceutical Design

Volumn 16, Issue 13, 2010, Pages 1504-1516

  van Linthout, Sophie ^a   Spillmann, Frank ^a   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diabetes mellitus; Diabetic cardiopathy; Dysfunction; Endothelial dysfunction; Glucose metabolism; High density lipoprotein; Remodeling

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR BI;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSE; HOMEOSTASIS; HUMANS; LIPOPROTEINS, HDL;

EID: 77952478120     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791051031     Document Type: Article

References (177)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR.High density lipoprotein as a protective factor against coronaryheart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
2. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease inhypercholesterolemic men: the Lipid Research Clinics CoronaryPrimary Prevention Trial. Circulation 1986; 74: 1217-25.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP,Knoke JD, et al. High-density lipoprotein cholesterol andcardiovascular disease. Four prospective American studies.Circulation 1989; 79: 8-15.
4. Mackness MI, Durrington PN. HDL, its enzymes and its potentialto influence lipid peroxidation. Atherosclerosis 1995; 115: 243-53.
5. Sugano M, Tsuchida K, Makino N. High-density lipoproteinsprotect endothelial cells from tumor necrosis factor-alpha-inducedapoptosis. Biochem Biophys Res Commun 2000; 272: 872-6.
6. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG,Miller NE, et al. Elevation of plasma high-density lipoproteinconcentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103: 108-12.
7. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM,et al. HDL cholesterol, very low levels of LDL cholesterol, andcardiovascular events. N Engl J Med 2007; 357: 1301-10.
8. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, HoughG, et al. Inflammatory/antiinflammatory properties of high-densitylipoprotein distinguish patients from control subjects better thanhigh-density lipoprotein cholesterol levels and are favorablyaffected by simvastatin treatment. Circulation 2003; 108: 2751-6.
9. Van Linthout S, Collen D, De Geest B. Effect of promoters andenhancers on expression, transgene DNA persistence, andhepatotoxicity after adenoviral gene transfer of humanapolipoprotein a-I. Hum Gene Ther 2002; 13: 829-40.
10. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G. Lipidprofiling of FPLC-separated lipoprotein fractions by electrosprayionization tandem mass spectrometry. J Lipid Res 2009; 50: 574-85.
11. Nofer JR, van der Giet M, Tolle M, Wolinska I, von WnuckLipinski K, Baba HA, et al. HDL induces NO-dependentvasorelaxation via the lysophospholipid receptor S1P3. J ClinInvest 2004; 113: 569-81.
12. Tölle M, SChuchardt M, van der Giet M. Relevance ofsphingolipids in pleiotropic effects of high density lipoproteins.Curr Pharm Design 2010; in press.
13. [13] Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984, 25: 1017-58.
14. Barter PJ, Rye KA. High density lipoproteins and coronary heartdisease. Atherosclerosis 1996, 121: 1-12.
15. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 actsequentially to remove cellular cholesterol and generatecholesterol-rich HDL. J Lipid Res 2006; 47: 2433-43.
16. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al.Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22: 352-5.
17. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression andApoA-I-mediated cholesterol efflux are regulated by LXR.Biochem Biophys Res Commun 2000; 274: 794-802.
18. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-OzcurumezM, Liebisch G, et al. ABCG1 (ABC8), the human homolog of theDrosophila white gene, is a regulator of macrophage cholesteroland phospholipid transport. Proc Natl Acad Sci USA 2000; 97:817-22.
19. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb VascBiol 2004; 24: 421-8.
20. Baldan A, Tarr P, Lee R, Edwards PA. ATP-binding cassettetransporter G1 and lipid homeostasis. Curr Opin Lipidol 2006; 17:227-32.
21. Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, DaughertyA, et al. Reduction in ABCG1 in Type 2 diabetic mice increasesmacrophage foam cell formation. J Biol Chem 2006; 281: 21216-24.
22. Mauldin JP, Nagelin MH, Wojcik AJ, Srinivasan S, Skaflen MD,Ayers CR, et al. Reduced expression of ATP-binding cassettetransporter G1 increases cholesterol accumulation in macrophagesof patients with type 2 diabetes mellitus. Circulation 2008; 117:2785-92.
23. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, et al.Polyunsaturated fatty acids and acetoacetate downregulate theexpression of the ATP-binding cassette transporter A1. Diabetes 2002; 51: 2922-8.
24. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipidadvanced glycosylation: pathway for lipid oxidation in vivo. ProcNatl Acad Sci USA 1993, 90: 6434-8.
25. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabeticcomplications. N Engl J Med 1988, 318: 1315-21.
26. Baynes JW, Thorpe SR. Role of oxidative stress in diabeticcomplications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
27. Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG,Heinecke JW, et al. Advanced glycation end product precursorsimpair ABCA1-dependent cholesterol removal from cells. Diabetes 2005; 54: 2198-205.
28. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR,Chiquoine EH, Billheimer JT, et al. Inflammation impairs reversecholesterol transport in vivo. Circulation 2009; 119: 1135-45.
29. Gantman A, Fuhrman B, Aviram M, Hayek T. High glucosestimulates macrophage SR-BI expression and induces a switch inits activity from cholesterol efflux to cholesterol influx. BiochemBiophys Res Commun 2010; 391(1): 523-8.
30. Ohgami N, Nagai R, Miyazaki A, Ikemoto M, Arai H, Horiuchi S,et al. Scavenger receptor class B type I-mediated reversecholesterol transport is inhibited by advanced glycation endproducts. J Biol Chem 2001; 276: 13348-55.
31. Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, et al.The ligand activity of AGE-proteins to scavenger receptors isdependent on their rate of modification by AGEs. Biochim BiophysActa 2007; 1772: 1192-8.
32. Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S,Wadsack C, et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. CircRes 2009; 104: 750-7.
33. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D,Kruijt JK, et al. Increased oxidative stress in scavenger receptor BIknockout mice with dysfunctional HDL. Arterioscler Thromb VascBiol 2007; 27: 2413-9.
34. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH,Rader DJ. Hepatic expression of scavenger receptor class B type I(SR-BI) is a positive regulator of macrophage reverse cholesteroltransport in vivo. J Clin Invest 2005; 115: 2870-4.
35. Shetty S, Eckhardt ER, Post SR, van der Westhuyzen DR.Phosphatidylinositol-3-kinase regulates scavenger receptor class Btype I subcellular localization and selective lipid uptake inhepatocytes. Arterioscler Thromb Vasc Biol 2006; 26: 2125-31.
36. Folli F, Saad MJ, Backer JM, Kahn CR. Regulation ofphosphatidylinositol 3-kinase activity in liver and muscle of animalmodels of insulin-resistant and insulin-deficient diabetes mellitus. JClin Invest 1993, 92: 1787-94.
37. Dietschy JM, Turley SD. Control of cholesterol turnover in themouse. J Biol Chem 2002; 277: 3801-4.
38. Rinninger F, Brundert M, Jackle S, Galle PR, Busch C, Izbicki JR,et al. Selective uptake of high-density lipoprotein-associatedcholesteryl esters by human hepatocytes in primary culture.Hepatology 1994, 19: 1100-14.
39. Trigatti B, Rigotti A, Krieger M. The role of the high-densitylipoprotein receptor SR-BI in cholesterol metabolism. Curr OpinLipidol 2000; 11: 123-31.
40. Van Craeyveld E, Gordts S, Feng Y, Jacobs F, De Geest B. Genetherapy to improve high density lipoprotein metabolism andfunction. Curr Pharm Design 2010; in press.
41. Yvan-Charvet L, Bobard A, Bossard P, Massiera F, Rousset X,Ailhaud G, et al. In vivo evidence for a role of adipose tissue SR-BIin the nutritional and hormonal regulation of adiposity andcholesterol homeostasis. Arterioscler Thromb Vasc Biol 2007; 27:1340-5.
42. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, KingBD, et al. Increased HDL cholesterol and apoA-I in humans andmice treated with a novel SR-BI inhibitor. Arterioscler ThrombVasc Biol 2009; 29: 2054-60.
43. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G,Barrett PH, et al. Triglyceride enrichment of HDL enhances in vivometabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-9.
44. Lottenberg SA, Lottenberg AM, Nunes VS, McPherson R, QuintaoEC. Plasma cholesteryl ester transfer protein concentration, high-density lipoprotein cholesterol esterification and transfer rates tolighter density lipoproteins in the fasting state and after a test mealare similar in Type II diabetics and normal controls.Atherosclerosis 1996, 127: 81-90.
45. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, ChapmanMJ. Atherogenic role of elevated CE transfer from HDL toVLDL(1) and dense LDL in type 2 diabetes: impact of the degreeof triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21: 282-8.
46. Arii K, Suehiro T, Yamamoto M, Ito H, Hashimoto K. Suppressionof plasma cholesteryl ester transfer protein activity in acutehyperinsulinemia and effect of plasma nonesterified fatty acid.Metabolism 1997, 46: 1166-70.
47. Riemens SC, Van Tol A, Stulp BK, Dullaart RP. Influence ofinsulin sensitivity and the TaqIB cholesteryl ester transfer proteingene polymorphism on plasma lecithin: cholesterol acyltransferaseand lipid transfer protein activities and their response tohyperinsulinemia in non-diabetic men. J Lipid Res 1999; 40: 1467-74.
48. Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A,Hashemi S. HbA1c negatively correlates with LCAT activity intype 2 diabetes. Diabetes Res Clin Pract 2008; 81: 38-41.
49. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ,Charlton F, et al. The impact of glycation on apolipoprotein A-Istructure and its ability to activate lecithin: cholesterolacyltransferase. Diabetologia 2007; 50: 643-53.
50. Riemens S, van Tol A, Sluiter W, Dullaart R. Elevated plasmacholesteryl ester transfer in NIDDM: relationships withapolipoprotein B-containing lipoproteins and phospholipid transferprotein. Atherosclerosis 1998, 140: 71-9.
51. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevantto common metabolic diseases. N Engl J Med 1989, 320: 1060-8.
52. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, TaskinenMR. Changes of lipolytic enzymes cluster with insulin resistancesyndrome. Botnia Study Group. Diabetologia 1995, 38: 344-50.
53. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity inskeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991, 11: 1192-203.
54. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, RaderDJ. Characterization of the lipolytic activity of endothelial lipase. JLipid Res 2002; 43: 921-9.
55. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K,et al. A novel endothelial-derived lipase that modulates HDLmetabolism. Nat Genet 1999; 21: 424-8.
56. Ishida T, Choi S, Kundu RK, Hirata K, Rubin EM, Cooper AD, etal. Endothelial lipase is a major determinant of HDL level. J ClinInvest 2003; 111: 347-55.
57. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition ofendothelial lipase causes increased HDL cholesterol levels in vivo.J Clin Invest 2003; 111: 357-62.
58. Shiu SW, Tan KC, Huang Y, Wong Y. Type 2 diabetes mellitusand endothelial lipase. Atherosclerosis 2008; 198: 441-7.
59. van Deursen D, Jansen H, Verhoeven AJ. Glucose increaseshepatic lipase expression in HepG2 liver cells through upregulationof upstream stimulatory factors 1 and 2. Diabetologia 2008; 51:2078-87.
60. Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A,et al. Hepatic lipase mRNA, protein, and plasma enzyme activity isincreased in the insulin-resistant, fructose-fed Syrian goldenhamster and is partially normalized by the insulin sensitizerrosiglitazone. Diabetes 2004; 53: 2893-900.
61. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, DugiKA. Low plasma adiponectin levels are associated with increasedhepatic lipase activity in vivo. Diabetes Care 2005; 28: 2181-6.
62. Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW,et al. Enhanced cellular uptake of remnant high-density lipoproteinparticles: a mechanism for high-density lipoprotein lowering ininsulin resistance and hypertriglyceridemia. Circ Res 2008; 103:159-66.
63. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A,Ehnholm C. Human plasma phospholipid transfer protein causeshigh density lipoprotein conversion. J Biol Chem 1993, 268: 4032-6.
64. Hirayama S, Miida T, Miyazaki O, Aizawa Y. Pre beta1-HDLconcentration is a predictor of carotid atherosclerosis in type 2diabetic patients. Diabetes Care 2007; 30: 1289-91.
65. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, MorseJS, et al. Change in alpha1 HDL concentration predicts progressionin coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23: 847-52.
66. Dallinga-Thie GM, van Tol A, Dullaart RP. Plasma pre beta-HDLformation is decreased by atorvastatin treatment in type 2 diabetesmellitus: Role of phospholipid transfer protein. Biochim BiophysActa 2009; 1791: 714-8.
67. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Ability ofreconstituted high density lipoproteins to inhibit cytokine-inducedexpression of vascular cell adhesion molecule-1 in humanumbilical vein endothelial cells. J Lipid Res 1999; 40: 345-53.
68. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phos-pholipid composition of reconstituted high density lipoproteinsinfluences their ability to inhibit endothelial cell adhesion moleculeexpression. J Lipid Res 2000; 41: 1261-7.
69. Nicholls SJ, Lundman P, Harmer JA, Cutri B, Griffiths KA, RyeKA, et al. Consumption of saturated fat impairs the anti-inflam-matory properties of high-density lipoproteins and endothelialfunction. J Am Coll Cardiol 2006; 48: 715-20.
70. Persegol L, Verges B, Foissac M, Gambert P, Duvillard L. Inabilityof HDL from type 2 diabetic patients to counteract the inhibitoryeffect of oxidised LDL on endothelium-dependent vasorelaxation.Diabetologia 2006; 49: 1380-6.
71. Patel S, Puranik R, Nakhla S, Lundman P, Stocker R, Wang XS, etal. Acute hypertriglyceridaemia in humans increases thetriglyceride content and decreases the anti-inflammatory capacityof high density lipoproteins. Atherosclerosis 2009; 204: 424-8.
72. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics ofapolipoproteins and associated proteins from plasma high-densitylipoproteins. Arterioscler Thromb Vasc Biol 2009; in press.
73. Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C,Dahllof B, et al. A proteomic study of the apolipoproteins in LDLsubclasses in patients with the metabolic syndrome and type 2diabetes. J Lipid Res 2005; 46: 1999-2006.
74. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serumamyloid A during metabolism of acute-phase HDL bymacrophages. Arterioscler Thromb Vasc Biol 2000; 20: 763-72.
75. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL--guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 144-53.
76. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series:The immune system and atherogenesis. Lipoprotein-associatedinflammatory proteins: markers or mediators of cardiovasculardisease? J Lipid Res 2005; 46: 389-403.
77. Persegol L, Foissac M, Lagrost L, Athias A, Gambert P, Verges B,et al. HDL particles from type 1 diabetic patients are unable toreverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007; 50: 2384-7.
78. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K,Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetesmellitus but are improved after extended-release niacin therapy.Circulation 2010; 12(1): 110-22.
79. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, SettleM, et al. Apolipoprotein A-I is a selective target for myelo-peroxidase-catalyzed oxidation and functional impairment insubjects with cardiovascular disease. J Clin Invest 2004; 114: 529-41.
80. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M,Shishehbor MH, et al. Serum myeloperoxidase levels indepen-dently predict endothelial dysfunction in humans. Circulation 2004;110: 1134-9.
81. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, etal. Association between myeloperoxidase levels and risk ofcoronary artery disease. JAMA 2001; 286: 2136-42.
82. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, etal.Glycation impairs high-density lipoprotein function.Diabetologia 2000; 43: 312-20.
83. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation ofparaoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides.Diabet Med 2008; 25: 1049-55.
84. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protectiveeffect of paraoxonase activity in high-density lipoproteins againsterythrocyte membranes peroxidation: a comparison betweenhealthy subjects and type 1 diabetic patients. J Clin EndocrinolMetab 2004; 89: 2957-62.
85. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-ParmoSL, La Du BN. Paraoxonase inhibits high-density lipoproteinoxidation and preserves its functions. A possible peroxidative rolefor paraoxonase. J Clin Invest 1998, 101: 1581-90.
86. Nobecourt E, Zeng J, Davies MJ, Brown BE, Yadav S, Barter PJ, etal. Effects of cross-link breakers, glycation inhibitors and insulinsensitisers on HDL function and the non-enzymatic glycation ofapolipoprotein A-I. Diabetologia 2008; 51: 1008-17.
87. Njajou OT, Kanaya AM, Holvoet P, Connelly S, Strotmeyer ES,Harris TB, et al. Association between oxidized LDL, obesity andtype 2 diabetes in a population-based cohort, the health, aging andbody composition study. Diabetes Metab Res Rev 2009; 25: 733-9.
88. Bielicki JK, Forte TM, McCall MR. Minimally oxidized LDL is apotent inhibitor of lecithin: cholesterol acyltransferase activity. JLipid Res 1996, 37: 1012-21.
89. Liu F, Huang L. Improving plasmid DNA-mediated liver genetransfer by prolonging its retention in the hepatic vasculature. JGene Med 2001; 3: 569-76.
90. Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, et al.Targeted disruption of the murine lecithin: cholesterolacyltransferase gene is associated with reductions in plasmaparaoxonase and platelet- activating factor acetylhydrolaseactivities but not in apolipoprotein J concentration. J Lipid Res 1999; 40: 1276-83.
91. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T.Inflammatory mediators and islet beta-cell failure: a link betweentype 1 and type 2 diabetes. J Mol Med 2003; 81: 455-70.
92. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, etal. Insulin-secreting beta-cell dysfunction induced by humanlipoproteins. J Biol Chem 2003; 278: 18368-75.
93. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S,et al. Low- and high-density lipoproteins modulate function,apoptosis, and proliferation of primary human and murinepancreatic beta-cells. Endocrinology 2009; 150: 4521-30.
94. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ,Vasanji Z, et al. Beta-cell ABCA1 influences insulin secretion,glucose homeostasis and response to thiazolidinedione treatment.Nat Med 2007; 13: 340-7.
95. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, FerdaoussiM, Yang JY, et al. Human high-density lipoprotein particlesprevent activation of the JNK pathway induced by human oxidisedlow-density lipoprotein particles in pancreatic beta cells.Diabetologia 2007; 50: 1304-14.
96. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, et al.Apolipoprotein A-I stimulates AMP-activated protein kinase andimproves glucose metabolism. Diabetologia 2007; 50: 1960-8.
97. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC,Penfold SA, et al. High-density lipoprotein modulates glucosemetabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103-11.
98. Rapizzi E, Taddei ML, Fiaschi T, Donati C, Bruni P, Chiarugi P.Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor. Cell Mol Life Sci 2009; 66: 3207-18.
99. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, VaddiK, et al. CCR2 modulates inflammatory and metabolic effects ofhigh-fat feeding. J Clin Invest 2006; 116: 115-24.
100. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. Theadipocyte-secreted protein Acrp30 enhances hepatic insulin action.Nat Med 2001; 7: 947-53.
101. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, etal. Enhanced muscle fat oxidation and glucose transport byACRP30 globular domain: acetyl-CoA carboxylase inhibition andAMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99: 16309-13.
102. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, etal. Adiponectin stimulates glucose utilization and fatty-acidoxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
103. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, YamaguchiH, et al. Decreased serum levels of adiponectin are a risk factor forthe progression to type 2 diabetes in the Japanese Population: theFunagata study. Diabetes Care 2003; 26: 2015-20.
104. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S,Matsuzawa Y, et al. Inflammatory markers, adiponectin, and riskof type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26:1745-51.
105. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R,Takefuji S, et al. Comparison of circulating adiponectin andproinflammatory markers regarding their association withmetabolic syndrome in Japanese men. Arterioscler Thromb VascBiol 2006; 26: 871-6.
106. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S,Tataranni PA, et al. Adiponectin and development of type 2diabetes in the Pima Indian population. Lancet 2002; 360: 57-8.
107. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T,Kuroe A, et al. Hypoadiponectinemia is associated with visceral fataccumulation and insulin resistance in Japanese men with type 2diabetes mellitus. Metabolism 2003; 52: 1274-8.
108. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U,Scholmerich J, et al. Adiponectin represents an independentcardiovascular risk factor predicting serum HDL-cholesterol levelsin type 2 diabetes. FEBS Lett 2003; 545: 103-4.
109. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationshipbetween adiponectin and glycemic control, blood lipids, andinflammatory markers in men with type 2 diabetes. Diabetes Care 2004; 27: 1680-7.
110. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, BoykoEJ, et al. Relationship of adiponectin to body fat distribution,insulin sensitivity and plasma lipoproteins: evidence forindependent roles of age and sex. Diabetologia 2003; 46: 459-69.
111. Cote M, Mauriege P, Bergeron J, Almeras N, Tremblay A,Lemieux I, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. JClin Endocrinol Metab 2005; 90: 1434-9.
112. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F,et al. Adiponectin is an important determinant of apoA-Icatabolism. Arterioscler Thromb Vasc Biol 2006; 26: 1364-9.
113. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H,Rothenbacher D. Relationship of adiponectin with markers ofsystemic inflammation, atherogenic dyslipidemia, and heart failurein patients with coronary heart disease. Clin Chem 2006; 52: 853-9.
114. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, RaheS, et al. Plasma adiponectin concentrations predict insulinsensitivity of both glucose and lipid metabolism. Diabetes 2003;52: 239-43.
115. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, etal. Adiponectin relationship with lipid metabolism is independentof body fat mass: evidence from both cross-sectional andintervention studies. J Clin Endocrinol Metab 2004; 89: 2665-71.
116. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT,Kochar A, et al. Effects of rosiglitazone on lipids, adipokines, andinflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.Arterioscler Thromb Vasc Biol 2006; 26: 624-30.
117. de Souza JA, Vindis C, Hansel B, Negre-Salvayre A, Therond P,Serrano CV, Jr., et al. Metabolic syndrome features small,apolipoprotein A-I-poor, triglyceride-rich HDL3 particles withdefective anti-apoptotic activity. Atherosclerosis 2008; 197: 84-94.
118. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, etal. Torcetrapib differentially modulates the biological activities ofHDL2 and HDL3 particles in the reverse cholesterol transportpathway. Arterioscler Thromb Vasc Biol 2009; 29: 268-75.
119. [119] Van Linthout S, Foryst-Ludwig A, Spillmann F, Peng J, Y. F,Meloni M, et al. Impact of HDL on adipose tissue metabolism andadiponectin expression. Atherosclerosis In Press.
120. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S,et al. L-4F treatment reduces adiposity, increases adiponectinlevels, and improves insulin sensitivity in obese mice. J Lipid Res 2008; 49: 1658-69.
121. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, etal. The L-4F mimetic peptide prevents insulin resistance throughincreased levels of HO-1, pAMPK, and pAKT in obese mice. JLipid Res 2009; 50: 1293-304.
122. Van Linthout S, Spillmann F, Riad A, Trimpert C, Lievens J,Meloni M, et al. Human apolipoprotein A-I gene transfer reducesthe development of experimental diabetic cardiomyopathy.Circulation 2008; 117: 1563-73.
123. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular andmolecular abnormalities in the vascular endothelium of diabetesmellitus. Annu Rev Med 1994, 45: 179-88.
124. McNally PG, Watt PA, Rimmer T, Burden AC, Hearnshaw JR,Thurston H. Impaired contraction and endothelium-dependentrelaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus. Clin Sci (Lond) 1994, 87: 31-6.
125. Cohen RA. Dysfunction of vascular endothelium in diabetesmellitus. Circulation 1993, 87: V67-76.
126. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal andcardiovascular events in patients with diabetes. J Hypertens 2006;24: 11-25.
127. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH,Skatchkov M, et al. Increased NADH-oxidase-mediated superoxideproduction in the early stages of atherosclerosis: evidence forinvolvement of the renin-angiotensin system. Circulation 1999; 99:2027-33.
128. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S,Vetter H. Upregulation of vascular angiotensin II receptor geneexpression by low-density lipoprotein in vascular smooth musclecells. Circulation 1997, 95: 473-8.
129. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulininduces upregulation of vascular AT1 receptor gene expression byposttranscriptional mechanisms. Circulation 1998, 98: 2453-60.
130. Nyby MD, Abedi K, Smutko V, Eslami P, Tuck ML. VascularAngiotensin type 1 receptor expression is associated with vasculardysfunction, oxidative stress and inflammation in fructose-fed rats.Hypertens Res 2007; 30: 451-7.
131. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D.Losartan, an angiotensin type 1 receptor antagonist, improvesendothelial function in non-insulin-dependent diabetes. J Am CollCardiol 2000; 36: 1461-6.
132. Oak JH, Cai H. Attenuation of angiotensin II signaling recoupleseNOS and inhibits nonendothelial NOX activity in diabetic mice.Diabetes 2007; 56: 118-26.
133. Cho HJ, Kim HS, Lee MM, Kim DH, Yang HJ, Hur J, et al.Mobilized endothelial progenitor cells by granulocyte-macrophagecolony-stimulating factor accelerate reendothelialization andreduce vascular inflammation after intravascular radiation.Circulation 2003; 108: 2918-25.
134. Gulati R, Jevremovic D, Witt TA, Kleppe LS, Vile RG, Lerman A,et al. Modulation of the vascular response to injury by autologousblood-derived outgrowth endothelial cells. Am J Physiol Heart CircPhysiol 2004; 287: H512-7.
135. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, PerrellaMA, et al. Enhanced inhibition of neointimal hyperplasia bygenetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-75.
136. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M,Murayama T, et al. Statin therapy accelerates reendothelialization:a novel effect involving mobilization and incorporation of bonemarrow-derived endothelial progenitor cells. Circulation 2002;105: 3017-24.
137. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, VerseydenC, de Boer HC, et al. Endothelial progenitor cell dysfunction: anovel concept in the pathogenesis of vascular complications of type1 diabetes. Diabetes 2004; 53: 195-9.
138. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ,Jacobowitz GR, et al. Human endothelial progenitor cells fromtype II diabetics exhibit impaired proliferation, adhesion, andincorporation into vascular structures. Circulation 2002; 106: 2781-6.
139. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ,McGrath LT, Henry WR, et al. Impaired endothelium-dependentand independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992, 35: 771-6.
140. Vetter R, Rehfeld U, Reissfelder C, Weiss W, Wagner KD,Gunther J, et al. Transgenic overexpression of the sarcoplasmicreticulum Ca2+ATPase improves reticular Ca2+ handling innormal and diabetic rat hearts. FASEB J 2002; 16: 1657-9.
141. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D,Escher F, et al. Prevention of cardiac fibrosis and left ventriculardysfunction in diabetic cardiomyopathy in rats by transgenicexpression of the human tissue kallikrein gene. FASEB J 2004; 18:828-35.
142. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, etal. Transgenic activation of the kallikrein-kinin system inhibitsintramyocardial inflammation, endothelial dysfunction andoxidative stress in experimental diabetic cardiomyopathy. FASEB J 2005; 19: 2057-9.
143. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, et al. Anti-inflammatory effects of atorvastatin improve leftventricular function in experimental diabetic cardiomyopathy.Diabetologia 2007; 50: 1977-86.
144. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, DhayatN, et al. Reduced MMP-2 activity contributes to cardiac fibrosis inexperimental diabetic cardiomyopathy. Basic Res Cardiol 2008;103: 319-27.
145. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, etal. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-32.
146. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cyto-chrome C-mediated caspase-3 activation pathway. Diabetes 2002;51: 1938-48.
147. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T,Kaneda Y, et al. Normalizing mitochondrial superoxide productionblocks three pathways of hyperglycaemic damage. Nature 2000;404: 787-90.
148. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, et al. Inhibition of p38 mitogen-activatedprotein kinase attenuates left ventricular dysfunction by mediatingpro-inflammatory cardiac cytokine levels in a mouse model ofdiabetes mellitus. Diabetologia 2006; 49: 2507-13.
149. Dewald O, Frangogiannis NG, Zoerlein M, Duerr GD, Klemm C,Knuefermann P, et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatoryreaction and depends on reactive oxygen species. Proc Natl AcadSci USA 2003; 100: 2700-5.
150. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiacmitochondria by overexpression of MnSOD reduces diabeticcardiomyopathy. Diabetes 2006; 55: 798-805.
151. Suzuki K, Murtuza B, Sammut IA, Latif N, Jayakumar J,Smolenski RT, et al. Heat shock protein 72 enhances manganesesuperoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection andapoptosis reduction. Circulation 2002; 106: I270-6.
152. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors asdeterminants of endothelium-dependent and endothelium-indepen-dent vascular reactivity in the general population. J Am CollCardiol 2001; 38: 1814-20.
153. Lupattelli G, Marchesi S, Roscini AR, Siepi D, Gemelli F, Pirro M,et al. Direct association between high-density lipoproteincholesterol and endothelial function in hyperlipemia. Am J Cardiol 2002; 90: 648-50.
154. O'Brien SF, Watts GF, Playford DA, Burke V, O'Neal DN, BestJD. Low-density lipoprotein size, high-density lipoproteinconcentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet Med 1997; 14: 974-8.
155. Feng Y, Jacobs F, Van Craeyveld E, Brunaud C, Snoeys J, Tjwa M,et al. Human ApoA-I transfer attenuates transplant arteriosclerosisvia enhanced incorporation of bone marrow-derived endothelialprogenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 278-83.
156. Feng Y, van Eck M, Van Craeyveld E, Jacobs F, Carlier V, VanLinthout S, et al. Critical role of scavenger receptor-BI-expressingbone marrow-derived endothelial progenitor cells in the attenuationof allograft vasculopathy after human apo A-I transfer. Blood 2009;113: 755-64.
157. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, et al. Sphingosine-1-phosphate stimulates the functionalcapacity of progenitor cells by activation of the CXCR4-dependentsignaling pathway via the S1P3 receptor. Arterioscler Thromb VascBiol 2007; 27: 275-82.
158. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ,Yasin M, et al. Effect of recombinant ApoA-I Milano on coronaryatherosclerosis in patients with acute coronary syndromes: arandomized controlled trial. JAMA 2003; 290: 2292-300.
159. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J,Heinonen TM, et al. Effects of reconstituted high-densitylipoprotein infusions on coronary atherosclerosis: a randomizedcontrolled trial. JAMA 2007; 297: 1675-82.
160. Nieuwdorp M, Vergeer M, Bisoendial RJ, op 't Roodt J, Levels H,Birjmohun RS, et al. Reconstituted HDL infusion restoresendothelial function in patients with type 2 diabetes mellitus.Diabetologia 2008; 51: 1081-4.
161. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF,Quan S, et al. D-4F induces heme oxygenase-1 and extracellularsuperoxide dismutase, decreases endothelial cell sloughing, andimproves vascular reactivity in rat model of diabetes. Circulation 2005; 111: 3126-34.
162. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, MorrisMA, Ley K, et al. Sphingosine-1 phosphate preventsmonocyte/endothelial interactions in type 1 diabetic NOD micethrough activation of the S1P1 receptor. Circ Res 2006; 99: 731-9.
163. Van Linthout S, Spillmann F, Lorenz M, Meloni M, Jacobs F,Egorova M, et al. Vascular-protective effects of high-densitylipoprotein include the downregulation of the angiotensin II type 1receptor. Hypertension 2009; 53: 682-7.
164. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME,Karas RH. A novel mechanism for the beneficial vascular effects ofhigh-density lipoprotein cholesterol: enhanced vasorelaxation andincreased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-72.
165. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, BinggeliC, et al. High-density lipoprotein restores endothelial function inhypercholesterolemic men. Circulation 2002; 105: 1399-402.
166. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F,Franceschini G. High-density lipoproteins protect isolated rat heartsfrom ischemia-reperfusion injury by reducing cardiac tumornecrosis factor-alpha content and enhancing prostaglandin release.Circ Res 2003; 92: 330-7.
167. Rossoni G, Gomaraschi M, Berti F, Sirtori CR, Franceschini G,Calabresi L. Synthetic high-density lipoproteins exert cardio-protective effects in myocardial ischemia/reperfusion injury. JPharmacol Exp Ther 2004; 308: 79-84.
168. Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J,Schober O, et al. High-density lipoprotein stimulates myocardialperfusion in vivo. Circulation 2004; 110: 3355-9.
169. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M,Herrgott I, et al. High-density lipoproteins and their constituent,sphingosine-1-phosphate, directly protect the heart againstischemia/reperfusion injury in vivo via the S1P3 lysophospholipidreceptor. Circulation 2006; 114: 1403-9.
170. Yeh CC, Li H, Malhotra D, Huang MC, Zhu BQ, Goetzl EJ, et al.Sphingolipid signaling and treatment during remodeling of theuninfarcted ventricular wall after myocardial infarction. Am JPhysiol Heart Circ Physiol 2009; 296: H1193-9.
171. Means CK, Brown JH. Sphingosine-1-phosphate receptorsignalling in the heart. Cardiovasc Res 2009; 82: 193-200.
172. Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, etal. Kallikrein gene delivery improves serum glucose and lipidprofiles and cardiac function in streptozotocin-induced diabeticrats. Diabetes 2005; 54: 1573-80.
173. Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Aktsignaling in mitochondrial survival pathway triggered by hypoxicpreconditioning. Circulation 2004; 109: 3042-9.
174. Bellosta S, Gomaraschi M, Canavesi M, Rossoni G, Monetti M,Franceschini G, et al. Inhibition of MMP-2 activation and releaseas a novel mechanism for HDL-induced cardioprotection. FEBSLett 2006; 580: 5974-8.
175. Barsotti A, Giannoni A, Di Napoli P, Emdin M. Energy metabo-lism in the normal and in the diabetic heart. Curr Pharm Des 2009;15(8): 836-40.
176. Karastergiou K, Kaski JC. Medical management of the diabeticpatient with coronary artery disease. Curr Pharm Des 2008; 14(25):2527-36.
177. Vitale C, Collin P. Optimization of cardiac metabolism in diabetesmellitus. Curr Pharm Des 2008; 14(25): 2537-50.